黃豔娟

黃豔娟

副教授

研究領域:創新藥物制劑(包括智能響應水凝膠遞藥系統,基于幹細胞/免疫細胞的仿生型遞藥系統,腫瘤靶向智能藥物遞送與控釋系統)的開發及其在臨床重大疾病中的預防與治療應用。

聯系郵箱: huangyj256@mail.sysu.edu.cn

個人主頁: https://scholar.google.com/citations?hl=zh-CN&user=s2nt9SIAAAAJ

個人簡介

黃豔娟,太阳集团1088vip,副教授,碩導。2020年畢業于太阳集团1088vip,獲藥劑學博士學位。先後主持國家自然基金青年項目、廣東省自然科學基金-青年提升項目、廣東省自然科學基金面上項目、廣東省區域聯合基金-青年基金、中國博士後基金面上項目、廣州市青年博士啟航項目、中山大學青年教師培育項目共8項課題。研究成果共發表SCI論文30餘篇,其中以第一作者/通訊作者(含共同)先後在Nat Commun、J Control Release、Acta Pharm Sin B、Biomaterials、ACS Nano、Chem Eng J、Asian J Pharm Sci、Acta Biomater、Int J Pharmaceut等國内外知名學術刊物發表論文17篇。申請發明專利7項,其中4項已授權。擔任ACS Appl. Mater. Interfaces、Int. J. Pharmaceut.、Acta Biomater.、Acs omega、Int J Biol Macromol等期刊審稿人。Chinese chemical letters、View雜志青年編委,pharmaceutics 雜志特刊主題"ROS-Mediated Nano Drug Delivery for Antitumor Therapy"客座編輯(歡迎投稿,截稿日期2025.02.28).

研究方向

創新藥物制劑(包括智能響應水凝膠遞藥系統,基于幹細胞/免疫細胞的仿生型遞藥系統,腫瘤靶向智能藥物遞送與控釋系統)的開發及其在臨床重大疾病中的預防與治療應用。

主持科研項目

(1)國家自然科學基金青年基金,2022.01至2024.12,30萬,主持;

(2)廣東省自然科學基金-青年提升,2024.01-2026.12,30萬,主持;

(3)廣東省自然科學基金-面上項目, 2025.01-2027.12,10萬,主持;

(4)廣州市基礎與應用基礎研究-青年博士“啟航”項目,2024.01-2025.12,5萬,主持;

(5)廣東省自然科學基金-面上項目,2021.01至2023.12,10萬,主持;

(6)廣東省區域聯合基金-青年基金,2020.10至2023.06,10萬,主持;

(7)中國博士後科學基金面上項目,2020.11至2023.06,8萬,主持;

(8)中山大學青年教師培育項目,2022.01至2023.06,5.9萬,主持。

代表性成果

  1. Y. Huang, Z. Guan, X. Dai, Y. Shen, Q. Wei, L. Ren, J. Jiang, Z. Xiao, Y. Jiang, D. Liu, Z. Huang, X. Xu, Y. Luo, C. Zhao*. Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer, Nature Communications, 12(1), (2021), 1-22.(中科院1區Top
  2. T. Zhang#, X. Shi#, Y. Huang*(共通訊), Y. Gong, Y. He, D. Xiao, S. Wang, C. Zhao*. Oxidized fucoidan-based nanocomposite hydrogel for cryptotanshinone delivery and prevention of postoperative abdominal adhesions, Journal of Controlled Release, 382 (2025) 113733. (中科院1區Top
  3. Y. Huang#(共一第一), M. Xia#, C. Xu, Z. Lin, M. Chen, X. Shi, Y. Ding, Y. Xiao, C. Zhao*, A GSH-responsive oxidative stress nanoamplifier for self-augmented chemo/chemodynamic therapy to reverse cisplatin resistance, Acta Biomaterialia, 193, (2025) 440-454.(中科院1區Top
  4. Y. Huang#(共一第一), X. Dai#, Y. Gong#, L. Ren, Y. Luo, Y. Sun, M. Chen, J. Jiang, Z. Guan, C. Zhao*, ROS-responsive sprayable hydrogel as ROS scavenger and GATA6+ macrophages trap for the prevention of postoperative abdominal adhesions, Journal of Controlled Release, 369 (2024) 573-590. (中科院1區Top
  5. T. Zhang#, Y. Huang#(共一第二), Y. Gong#, X. Shi, D. Xiao, L. Ren, X. Dai, Z. Zeng, C. Zhao*, A ROS-responsive and scavenging hydrogel for postoperative abdominal adhesion prevention, Acta Biomaterialia, 184, (2024), 98-113.(中科院1區Top
  6. J. Jiang#, Y. Huang#(共一第二), Z. Zeng and C. Zhao*. Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy, ACS Nano, 17, (2023), 843–884.(中科院1區Top
  7. Y. Huang#, Z. Guan#, Lingling Ren#, Y. Luo, M. Chen, Y. Sun, Y. He, Z. Zeng, X. Dai, J. Jiang, Z. Huang, C. Zhao*. Bortezomib prodrug catalytic nanoreactor for chemo/chemodynamic therapy and macrophage re-education, Journal of Controlled Release, 350, (2022), 332-349.(中科院1區Top
  8. J. Chen#, X. Tan#, Y. Huang#, *(共一第三,共通訊), C. Xu, Z. Zeng, T. Shan, Z. Guan, X. Xu, Z. Huang, C. Zhao*. Reactive oxygen species-activated self-amplifying prodrug nanoagent for tumor-specific Cu-chelate chemotherapy and cascaded photodynamic therapy, Biomaterials, 284, (2022) 121513.(中科院1區Top
  9. Y. Huang#, Z. Xiao#, Z. Guan, Y. Shen, Y. Jiang, X. Xu, Z. Huang, C. Zhao*. A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways, Journal of Controlled Release, 319, (2020), 119-134.(中科院1區Top
  10. Y. Huang, Z. Xiao, Z. Guan, Z. Zeng, Y. Shen, X. Xu, C. Zhao*. Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption, Acta Pharmaceutica Sinica B, 10(12), (2020), 2384-2403.(中科院1區Top
  11. Y. Huang#, Y. Jiang#, Z. Xiao#, Y. Shen, L. Huang, X. Xu, G. Wei, C. Xu, C. Zhao*. Three birds with one stone: A ferric pyrophosphate based nanoagent for synergetic NIR-triggered photo/chemodynamic therapy with glutathione depletion, Chemical Engineering Journal, 380, (2020), 122369.(中科院1區Top
  12. Y. Huang#, H. Lai#, J. Jiang#, X. Xu, Z. Zeng, L. Ren, Q. Liu, M. Chen, T. Zhang, X. Ding, C. Zhao, S. Cui*. pH-activatable oxidative stress amplifying dissolving microneedles for combined chemo-photodynamic therapy of Melanoma, Asian Journal of Pharmaceutical Sciences,17, (2022), 679-696.(中科院1區Top
  13. Y. Huang#, T. Zhang#, Q. Wei#, Z. Zeng, Y. Gong, X. Xu, M. Chen, C. Zhao*. “NIR-triggered ROS storage” photodynamic intraocular implant for high-efficient and safe posterior capsular opacification prevention, Asian Journal of Pharmaceutical Sciences, 17(6), (2022), 838-854.(封面論文,中科院1區Top
  14. Y. Huang#, X. Dai#, Z. Guan#, D. Liu, L. Ren, M. Chen, Z. Zeng, J. Jiang, Y. Luo, Y. He, M. Huang, C. Zhao*. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking, International journal of pharmaceutics, 622,(2022), 121897(藥學2區Top
  15. 黃豔娟,趙春順,關梓琳。一種近紅外光激活型巨噬細胞-納米前藥靶向遞藥系統的構建及其應用,專利号:202110760793.7,發明授權